Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NYSE:BHVN NASDAQ:IMMX NASDAQ:MLYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$37.39-0.5%$30.43$22.24▼$46.00$2.23B0.541.16 million shs476,106 shsBHVNBiohaven$16.05+0.6%$11.49$7.48▼$18.57$2.40B1.283.90 million shs1.95 million shsIMMXImmix Biopharma$10.45+1.1%$9.24$1.94▼$11.61$562.61M0.092.02 million shs1.32 million shsMLYSMineralys Therapeutics$29.12+5.2%$27.09$12.59▼$47.65$2.28B0.661.71 million shs1.72 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%-0.84%+32.84%+7.99%+4.23%BHVNBiohaven0.00%+0.88%+46.92%+73.47%+8.89%IMMXImmix Biopharma0.00%+3.61%+30.39%+20.37%+304.70%MLYSMineralys Therapeutics0.00%+3.79%+16.88%-1.91%+90.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$37.39-0.5%$30.43$22.24▼$46.00$2.23B0.541.16 million shs476,106 shsBHVNBiohaven$16.05+0.6%$11.49$7.48▼$18.57$2.40B1.283.90 million shs1.95 million shsIMMXImmix Biopharma$10.45+1.1%$9.24$1.94▼$11.61$562.61M0.092.02 million shs1.32 million shsMLYSMineralys Therapeutics$29.12+5.2%$27.09$12.59▼$47.65$2.28B0.661.71 million shs1.72 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%-0.84%+32.84%+7.99%+4.23%BHVNBiohaven0.00%+0.88%+46.92%+73.47%+8.89%IMMXImmix Biopharma0.00%+3.61%+30.39%+20.37%+304.70%MLYSMineralys Therapeutics0.00%+3.79%+16.88%-1.91%+90.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$40.899.36% UpsideBHVNBiohaven 2.67Moderate Buy$21.6334.74% UpsideIMMXImmix Biopharma 2.67Moderate Buy$20.6797.77% UpsideMLYSMineralys Therapeutics 2.63Moderate Buy$49.3369.41% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, BHVN, MLYS, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026BHVNBiohaven Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.006/29/2026BHVNBiohaven Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$12.00 ➝ $11.006/26/2026BHVNBiohaven Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/24/2026AGIOAgios Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/18/2026IMMXImmix Biopharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/18/2026IMMXImmix Biopharma Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/17/2026IMMXImmix Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$19.006/11/2026AGIOAgios Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$36.00 ➝ $31.006/2/2026BHVNBiohaven Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/1/2026MLYSMineralys Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/1/2026MLYSMineralys Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M41.15N/AN/A$20.46 per share1.83BHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/AIMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$8.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)BHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%8/14/2026 (Estimated)MLYSMineralys Therapeutics-$154.65M-$2.05N/AN/AN/AN/A-27.92%-26.98%8/11/2026 (Estimated)Latest IMMX, BHVN, MLYS, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026AGIOAgios Pharmaceuticals-$1.6728N/AN/AN/A$26.42 millionN/A5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A5/6/2026Q1 2026MLYSMineralys Therapeutics-$0.51-$0.47+$0.04-$0.47N/AN/A5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/A4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59BHVNBiohaven1.877.417.41IMMXImmix BiopharmaN/A8.758.75MLYSMineralys TherapeuticsN/A44.3344.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ABHVNBiohaven88.78%IMMXImmix Biopharma11.26%MLYSMineralys Therapeutics84.46%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%BHVNBiohaven13.80%IMMXImmix Biopharma30.30%MLYSMineralys Therapeutics18.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableBHVNBiohaven239150.56 million129.78 millionOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableMLYSMineralys Therapeutics2882.50 million66.87 millionOptionableIMMX, BHVN, MLYS, and AGIO HeadlinesRecent News About These CompaniesIs Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?July 2, 2026 | insidermonkey.com5 Hidden Multibagger Stocks to Buy Right NowJuly 2, 2026 | insidermonkey.comEric Warren Sells 104,124 Shares of Mineralys Therapeutics (NASDAQ:MLYS) StockJuly 2, 2026 | americanbankingnews.comMineralys Therapeutics, Inc. $MLYS Shares Purchased by Pictet Asset Management Holding SAJuly 2, 2026 | marketbeat.comJon Congleton Sells 75,000 Shares of Mineralys Therapeutics (NASDAQ:MLYS) StockJuly 2, 2026 | americanbankingnews.comMineralys Therapeutics (NASDAQ:MLYS) CEO Sells 75,000 Shares of StockJuly 1, 2026 | insidertrades.comWhat a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA DecisionJune 23, 2026 | fool.comDaphne Karydas Sells 3,000 Shares of Mineralys Therapeutics (NASDAQ:MLYS) StockJune 18, 2026 | insidertrades.comFindell Capital Management LLC Decreases Position in Mineralys Therapeutics, Inc. $MLYSJune 18, 2026 | marketbeat.comCatalio Capital Management LP Takes Position in Mineralys Therapeutics, Inc. $MLYSJune 18, 2026 | marketbeat.comMineralys Therapeutics, Inc. $MLYS Shares Purchased by Artia Global Partners LPJune 18, 2026 | marketbeat.comMineralys: Limited Differentiation Makes Lorundrostat A Weak CompetitorJune 17, 2026 | seekingalpha.comMineralys Therapeutics (MLYS) Prices $150M Public Offering of Common StockJune 17, 2026 | finance.yahoo.comMineralys Therapeutics (NASDAQ:MLYS) Insider Sells $114,600.00 in StockJune 17, 2026 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 9,890 SharesJune 17, 2026 | marketbeat.comPolar Capital Holdings Plc Buys 342,365 Shares of Mineralys Therapeutics, Inc. $MLYSJune 17, 2026 | marketbeat.comMineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic AnalysisJune 14, 2026 | quiverquant.comQMineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)June 14, 2026 | globenewswire.comInsider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 2,170 Shares of StockJune 12, 2026 | marketbeat.comDavid Malcom Rodman Sells 6,349 Shares of Mineralys Therapeutics (NASDAQ:MLYS) StockJune 12, 2026 | marketbeat.comMineralys Therapeutics (MLYS) to Repurchase Potential Royalties for LorundrostatJune 11, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMX, BHVN, MLYS, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$37.39 -0.19 (-0.51%) Closing price 04:00 PM EasternExtended Trading$37.39 0.00 (0.00%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Biohaven NYSE:BHVN$16.05 +0.09 (+0.56%) Closing price 03:59 PM EasternExtended Trading$16.14 +0.09 (+0.54%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Immix Biopharma NASDAQ:IMMX$10.45 +0.11 (+1.06%) Closing price 04:00 PM EasternExtended Trading$10.62 +0.17 (+1.64%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Mineralys Therapeutics NASDAQ:MLYS$29.12 +1.43 (+5.16%) Closing price 04:00 PM EasternExtended Trading$29.12 0.00 (0.00%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
